Kanokphorn Thonglert

Kanokphorn Thonglert

Auto-generated profile, based on publicly available information

Kanokphorn Thonglert

Division of Radiation Oncology, Department of Radiology, Faculty of Medicine, Chulalongkorn University, King Chulalongkorn Memorial Hospital, Thai Red Cross Society, Bangkok, Thailand

Research Focus & Metrics

Academic Career Length

2Years (2025-Present)

(Calculated once Scilit publication data is synced: current year − year of first publication + 1)

Representative Publications

View All Publications
31 May 2025 in Radiotherapy and Oncology
Verified
Journal Article
Closed access
JTJoseph Tsai
Joseph Tsai
CGClemens Grassberger
Clemens Grassberger
MNMatthew J. Nyflot
Matthew J. Nyflot
KTKanokphorn Thonglert
Kanokphorn Thonglert
PZPeter Zaki
Peter Zaki
SBStephen R Bowen
Stephen R Bowen

2 July 2025 in Clinical and Translational Radiation Oncology
Verified
Journal Article
Open access
KTKanokphorn Thonglert
Kanokphorn Thonglert
MGMatthew D. Greer
Matthew D. Greer
SSStephanie Schaub
Stephanie Schaub
SBStephen R. Bowen
Stephen R. Bowen
AMAnthony M. Menghini
Anthony M. Menghini
SASmith Apisarnthanarax
Smith Apisarnthanarax
Although simultaneous integrated boost and protection with proton beam therapy (SIB-PBT) facilitates tumor dose escalation while maintaining organ-at-risk (OAR) dose constraints, clinical outcomes are limited. This study assessed the safety and efficacy of using the SIB-PBT technique in hepatocellular carcinoma (HCC) patients. We reviewed 47 patients with HCC who underwent SIB-PBT between 2014–2021. The radiation dose ranged from 36-67.5 Gy(RBE) in 15 fractions. SIB-PBT was used for the following reasons: minimize high-dose exposure to organs-at-risk (OARs) (n = 22, 47 %), treat targets with different dose levels (n = 6, 13 %), or both (n = 19, 40 %). Survival, local control, and toxicities were assessed using Kaplan-Meier, Fine-Gray cumulative incidence, and descriptive statistics, respectively. Forty-one patients (87 %) had tumors located ≤2 cm from luminal gastrointestinal (GI) OARs. The median tumor diameter was 9.2 cm (range, 2.0–21.5 cm). The median EQD2 D50%, D95% and D99% of gross tumor volume were 79.8 (range, 51.1–85.9), 66.7 (range, 36.9–84.6) and 50.2 (range, 34.1–83.6) Gy(RBE)10, respectively. Most patients (91 %) received a D0.5 cc of <45 Gy(RBE) to luminal GI OARs. At a median follow-up of 22 months (range, 0.8–77.0 months), the 2-year cumulative incidence of local failure was 12 %. The 2-year progression-free survival and overall survival rates were 12 % (95 % CI 4.7–23.4 %), and 49 % (95 % CI, 33.2–63.2 %), respectively. One patient experienced grade 3 acute nausea/vomiting. No GI bleeding/ulcers or grade 4 + toxicity were observed. CP + 2 occurred in 5 patients. SIB-PBT enables OAR protection along with heterogeneous tumor dose escalation and is a safe and effective treatment for HCC tumors.

20 November 2025 in International Journal of Radiation Oncology - Biology - Physics (IJROBP)
Verified
Journal Article
Closed access
KTKanokphorn Thonglert
Kanokphorn Thonglert
SASmith Apisarnthanarax
Smith Apisarnthanarax
BYBeow Y. Yeap
Beow Y. Yeap
MHMolly E. Havard
Molly E. Havard
SSStephanie K. Schaub
Stephanie K. Schaub
CGClemens Grassberger
Clemens Grassberger

22 May 2026 in International Journal of Radiation Oncology - Biology - Physics (IJROBP)
Verified
Journal Article
Closed access
KTKanokphorn Thonglert
Kanokphorn Thonglert
MGMatthew D. Greer
Matthew D. Greer
SSStephanie K. Schaub
Stephanie K. Schaub
SBStephen R. Bowen
Stephen R. Bowen
MNMatthew J. Nyflot
Matthew J. Nyflot
SASmith Apisarnthanarax
Smith Apisarnthanarax

27 December 2025 in Advances in Radiation Oncology
Verified
Journal Article
Open access
KTKanokphorn Thonglert
Kanokphorn Thonglert
JTJoseph Tsai
Joseph Tsai
WMWayne L. Monsky
Wayne L. Monsky
AAAugust C. Anderson
August C. Anderson
CGClemens Grassberger
Clemens Grassberger
SASmith Apisarnthanarax
Smith Apisarnthanarax
Data on the safety and efficacy of external beam radiation therapy (EBRT) after yttrium 90 transarterial radioembolization (TARE) for hepatocellular carcinoma (HCC) are limited. We report our experience using EBRT to treat HCC patients previously treated with TARE. We retrospectively analyzed 31 HCC patients who received EBRT following TARE. Eighteen (58%) were treated with photon therapy, and 13 (42%) with proton therapy. Eighteen patients (58%) had been previously treated with TARE within the EBRT-treated lesion, with a median total dose of 72 mCi (range, 49-272). Twenty-one patients (68%) had prior TARE outside the EBRT zone, with a median total dose of 84 mCi (range, 21-330). Toxicities and survival outcomes were analyzed. The number of prior TARE treatments ranged from 1 to 5: 14 patients (45%) received 1, and 17 (55%) received 2 or more. Indications for EBRT included incomplete TARE response (n = 2), technical TARE limitations (n = 25), and other reasons (n = 4). The median tumor size was 3.8 cm (range, 1.6-19.4). Most patients (87%) had a Child-Pugh (CP)-A score. With a median follow-up of 30 months, the 2-year progression-free survival and overall survival rates were 18% and 43%, respectively. The 2-year cumulative incidence of local failure was 7%. CP+2 progression was observed in 4 patients (13%). There was no significant difference in local failure or CP+2 rates based on the EBRT target location relative to prior TARE. Grade 3+ biliary complications occurred in 3 patients (10%): 2 biloma and 1 biliary stricture. All 3 patients had received at least 2 prior TARE treatments that overlapped with the area treated with EBRT and had tumors located near the central bile duct. EBRT for HCC patients previously treated with yttrium 90 is feasible and offers excellent local control. Liver dysfunction and biliary toxicities are potential complications and should be weighed against the clinical benefits.

11 July 2026 in SSRN Electronic Journal
Verified
Preprint
Open access
JSJiraporn Suntiruamjairucksa
Jiraporn Suntiruamjairucksa
NANapapat Amornwichet
Napapat Amornwichet
CKChonlakiet Khorprasert
Chonlakiet Khorprasert
PAPetch Alisanant
Petch Alisanant
KTKanokphorn Thonglert
Kanokphorn Thonglert
Background and PurposeThe benefit of rectal spacers in cervical cancer remains inconclusive, and evidence in MRI-guided adaptive brachytherapy (MR-IGABT) is limited. This prospective randomized controlled trial evaluated effects of hyaluronate gel injection (HGI) in cervical cancer patients undergoing MR-IGABT.Materials and MethodsCervical cancer patients receiving definitive chemoradiation with MR-IGABT were randomized 1:1 to HGI or non-HGI groups. In the HGI arm, 2–6 cc of hyaluronate gel was injected into the rectocervical space during each brachytherapy fraction to achieve ≥1-cm cervico-rectal separation. Primary endpoint was per-fraction rectal D2cc EQD2. Secondary endpoints included cumulative dose-volume parameters, toxicities, spacer geometry analysis, and patient-reported quality of life (QOL).ResultsTwenty-six patients were analyzed (13 per arm; mean follow-up of 16.8 ± 6.4 months). No significant difference was observed in per-fraction rectal D2cc (3.8 ± 0.7 Gy/Fx vs 4.1 ± 0.7 Gy/Fx; p=0.206) or cumulative rectal D2cc (65.9 ± 5.6 vs 65.9 ± 4.3 Gy; p=0.999). The bladder D2cc, CTVHR D90 and CTVHR D98 were similar between groups. Cumulative sigmoid D2cc was significantly higher in the HGI arm (66.8 ± 4.9 vs 62.8 ± 4.7 Gy; p=0.044), yet remained within constraints. Rectal D2cc correlated negatively with post-HGI rectocervical distance (R=−0.55, p<0.001). No grade ≥3 toxicities were observed, and QOL changes were comparable between arms. No serious HGI-related adverse events occurred.ConclusionHGI is safe and feasible in MR-IGABT for cervical cancer. Although it did not significantly reduce rectal dose, correlation between increased rectocervical distance and lower rectal dose supports its potential benefit, highlighting the need for future studies to optimize patient selection and spacer deployment technique.